Deciphera Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Deciphera Pharmaceuticals's estimated annual revenue is currently $91.4M per year.
- Deciphera Pharmaceuticals received $128.0M in venture funding in October 2017.
- Deciphera Pharmaceuticals's estimated revenue per employee is $275,422
- Deciphera Pharmaceuticals's total funding is $886.5M.
- Deciphera Pharmaceuticals's current valuation is $518.7M. (January 2022)
- Deciphera Pharmaceuticals has 332 Employees.
- Deciphera Pharmaceuticals grew their employee count by -26% last year.
Deciphera Pharmaceuticals Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a 'switched off or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Deciphera Pharmaceuticals News
... Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals ... Johnson & Johnson is usually the first pharma company to report...
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting. ULK Inhibitor DCC-3116 Shown to Inhibit...
Deciphera Pharmaceuticals Inc. is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of...
Deciphera Announces Positive CHMP Opinion for QINLOCK®for the Treatment of Fourth-line Gastrointestinal Stromal Tumor - European Commission Decision Anticipated by the Fourth Quarter of 2021 - Waltham, MA - September 17, 2021 - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage ...
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Deciphera Pharmaceuticals Funding
|2003-12-24||$15.0M||Lead Investor: Undis||Article|
|2015-09-22||$75.0M||B||New Leaf Venture Partners||Article|
|2016-01-06||$90.0M||B||New Leaf Venture Partners||Article|
|2017-06-05||$52.0M||Undisclosed||Viking Global Investors LP||Article|